Search

The article focuses on the increasing trend of Bulldog Frenchies as pets, highlighting the negative impact of dermatological issues, including atopic dermatitis, which arises due to their anatomical features. It discusses common dermatological conditions, such as otitis and intertrigo, prevalent in this breed due to their facial conformation, emphasizing the need for a multimodal approach to diagnosis and treatment to ensure long-term management and caregiver involvement.

A recent study conducted at Hiroshima University in Japan has found that combining the drug lebrikizumab with topical corticosteroids improves patient-reported outcomes in Japanese individuals with moderate-to-severe atopic dermatitis. The study involved 286 patients who were randomized to receive either placebo and topical corticosteroids, lebrikizumab every 4 weeks with topical corticosteroids, or lebrikizumab every 2 weeks with topical corticosteroids. The patients who received lebrikizumab in combination with topical corticosteroids showed significant and clinically meaningful improvements compared to those who received placebo and topical corticosteroids. This research provides valuable insights into potential treatment options for atopic dermatitis. [Extracted from the article]

A recent report from the University of Rochester highlights common targets for the treatment and prevention of atopic dermatitis (AD) and IgE-mediated food allergy (IgE-FA). The research emphasizes the shared pathophysiological features of these conditions, including epithelial barrier dysfunction, immune abnormalities, and microbial dysbiosis. The study suggests that targeted biologic therapies, such as dupilumab and omalizumab, may reduce symptom burden in pediatric populations. However, further research is needed to determine the potential for disease remission and prevention. The report calls for consistent age stratification and standardized regimens in future studies to improve interpretation and treatment outcomes. [Extracted from the article]

A recent study from the University of Southampton in the United Kingdom has highlighted the increased frequency of ocular adverse effects in patients with atopic dermatitis (AD) who are treated with the monoclonal antibody therapy dupilumab. To address this issue, the British Association of Dermatologists (BAD) and Royal College of Ophthalmologists collaborated on a consensus guidance for managing dupilumab-related ocular surface disorders (DROSD). The recommendations provided in the guidance cover both dermatology and ophthalmology management and apply to patients of all ages. The study concludes that while the risk of ocular adverse effects should not deter clinicians or patients from using dupilumab, it is important for clinicians to be aware of these effects and follow the recommended pathways for assessment and management. [Extracted from the article]

Keymed Biosciences Inc. has received marketing approval from the National Medical Products Administration (NMPA) of China for their new drug, Stapokibart, which is an anti-IL-4Ra monoclonal antibody used to treat moderate-to-severe atopic dermatitis in adults. The approval was based on a Phase III study that showed Stapokibart achieved the co-primary endpoints of at least a 75% improvement in Eczema Area and Severity Index (EASI-75) and an Investigator's Global Assessment (IGA) score of 0 or 1 with a reduction of =2 points from baseline at week 16. The study also demonstrated sustained clinical benefits and a good safety profile with long-term treatment. At week 52, the rates of achieving EASI-75, EASI-90, and an IGA score of 0 or 1 point with a reduction of =2 points from baseline were high in the Stapokibart group. The drug was well-tolerated and had consistent safety profiles throughout the study. [Extracted from the article]

A recent study conducted at the University of Abuja focused on atopic dermatitis (AD) in adults, a condition characterized by eczematous lesions on the skin. The study aimed to describe the prevalence, clinical pattern, and contact sensitization of adults with AD. Out of 2,177 patients, only 38 adults were diagnosed with AD, with two-thirds of them having adult-onset AD. The majority of patients presented with chronic eczema, and contact sensitivity to preservatives was observed. The study concluded that adult-onset AD is more common than childhood-onset AD in adults and that individuals with AD tend to develop contact sensitivity to preservatives. [Extracted from the article]

A recent study conducted at the University Hospital of Amiens in France aimed to understand the clinical characteristics and therapeutic management of atopic dermatitis (AD) in elderly patients compared to young adult patients. The study found that elderly patients with AD had less head-and-neck and extremity involvement and were less affected by generalized forms of the disease compared to young adults. However, both age groups experienced similar disease severity and had a substantial impact on sleep and psychiatric comorbidities. The researchers suggest that better understanding of AD in elderly patients and the development of age-specific treatment guidelines could help dermatologists manage the disease in older individuals. [Extracted from the article]

A recent study conducted at the University of Medicine and Pharmacy Craiova in Romania has explored the off-label uses of Abrocitinib, an oral small-molecule Janus Kinase 1 (JAK1) inhibitor primarily approved for treating moderate-to-severe atopic dermatitis (AD) in adults and adolescents aged 12 and older. The study identified 37 papers reporting on the use of Abrocitinib in various conditions other than AD, including vitiligo, prurigo nodularis, hand eczema, lichen sclerosus, chronic pruritus of unknown origin, pityriasis rubra pilaris alopecia areata, erythematotelangiectatic rosacea, and steroid-induced rosacea. The majority of the reviewed cases reported favorable clinical outcomes and satisfactory results, except for one isolated case of erythematotelangiectatic rosacea. Further information on this research can be obtained from the University of Medicine and Pharmacy Craiova. [Extracted from the article]

A recent report from Osaka University in Japan discusses the use of dupilumab, an anti-IL-4Ra antibody, as a therapeutic agent for atopic dermatitis (AD), a chronic eczematous skin disease. The study aimed to identify biomarkers and patient-related factors that could predict the effectiveness of dupilumab treatment. The researchers found that baseline biomarkers such as lactate dehydrogenase (LDH) and periostin, as well as clinical factors like comorbidity of food allergy and duration of severe disease, could be useful indicators for selecting dupilumab as a systemic treatment for AD. The research suggests that these factors can help predict the efficacy of dupilumab. [Extracted from the article]

This article provides information about a newly launched clinical trial, NCT06585202, which is a Phase 2 open-label study investigating the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in participants with moderate to severe atopic dermatitis. The study will be conducted over a period of 12 weeks and aims to assess the incidence and severity of treatment emergent adverse events, as well as changes in Eczema Area and Severity Index (EASI) and other outcome measures. The trial is currently recruiting participants and is being conducted in the United States. [Extracted from the article]

A recent study from Oregon Health & Science University (OHSU) provides new insights into the use of oral JAK inhibitors for atopic dermatitis (AD). JAK inhibitors have shown promising efficacy in phase 3 trials and have a rapid onset of action. However, their use is not appropriate for all AD patients, and dermatologists should carefully consider their use. The study provides guidance on prescribing JAK inhibitors, including patient selection, dosing, monitoring, and long-term use. It also highlights the need for future studies to assess the safety and durability of JAK inhibitor use in AD patients. The decision to use JAK inhibitors should be made collaboratively between the patient and provider, taking into account disease severity and individual risk factors. [Extracted from the article]

A recent study conducted by researchers at Gunma University Graduate School of Medicine in Japan explored the effectiveness of pulsed dye laser (PDL) in treating facial redness associated with atopic dermatitis (AD). The study involved three adult AD patients who underwent multiple PDL treatments at regular intervals. The results showed significant improvement in facial erythema and associated AD symptoms without severe complications. The researchers concluded that PDL could be a promising adjunctive therapy for managing refractory facial redness in adult AD patients, although further research is needed to fully understand its immunomodulatory effects. [Extracted from the article]

A new report from Taipei Veterans General Hospital in Taiwan explores the association between atopic dermatitis (AD) and venous thromboembolism (VTE) in adults. The study, which included a total of 284,858 participants, found that adults with AD had a significantly increased risk of developing VTE compared to those without AD. The absolute risk difference, however, was small. The researchers suggest that adults with AD who present with symptoms suggestive of VTE should undergo cardiovascular examination and management. Further research is needed to understand the underlying pathophysiology of the association between AD and VTE. [Extracted from the article]

A recent study conducted by researchers at Chengdu University of Traditional Chinese Medicine in Chengdu, China, explored the relationship between atopic dermatitis (AD) and microbial communities. The study analyzed the oral, skin, and gut microbiota of children with AD and healthy children using gene sequencing. The results showed reduced microbiota diversity in children with AD, as well as downregulated metabolic pathways. The study provides a more comprehensive understanding of the role of microbiota in AD and suggests new directions for diagnosis, treatment, and prognosis. [Extracted from the article]

A new report from researchers at Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico in Milan, Italy, discusses the long-term efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis (AD). The study, which included 2,576 patients, found that the achievement of minimal disease activity (MDA) optimal treatment target criteria increased over time, with 54.7% of patients reaching the criteria at 48 months of follow-up. Adverse events were mild and led to treatment discontinuation in less than 1% of patients. The researchers concluded that dupilumab is highly effective and safe for long-term use in patients with moderate-to-severe AD. Further research is needed to explore the impact of comorbidities and disease duration on the response to dupilumab and other treatments for AD. [Extracted from the article]

A recent study conducted at Massachusetts General Hospital evaluated the impact of dupilumab, a biologic agent, on pediatric patients with atopic dermatitis (AD). The study utilized electronic health records from multiple healthcare organizations across the United States and found that treatment with dupilumab resulted in a lowered risk of new-onset comorbidities, including asthma, allergic rhinitis, infections, psychiatric disorders, and neurologic and developmental disorders. The positive effects were more pronounced in younger children with AD. This research provides new insights into the potential benefits of dupilumab therapy for pediatric patients with AD. [Extracted from the article]

A recent report discusses research findings on atopic dermatitis, a skin condition characterized by inflammation. The study focused on PF-06817024, a humanized antibody that has the potential to inhibit type 2 inflammation. The research found that PF-06817024 showed promise in improving symptoms and reducing disease severity in patients with chronic rhinosinusitis with nasal polyps and moderate-to-severe atopic dermatitis. However, further research is needed to confirm the clinical benefits and safety of PF-06817024 as a treatment for allergic diseases. The study was registered on ClinicalTrials.gov. [Extracted from the article]

A recent study conducted by Bahcesehir University Faculty of Medicine in Turkey examined the ocular surfaces of children with atopic dermatitis (AD). The study found that pediatric patients with AD may experience significant changes in conjunctival histopathology, which can be detected through tests measuring tear film. The majority of children with AD were shown to have dry eye. These findings provide valuable insights into the ocular manifestations of AD in children. [Extracted from the article]

A recent study conducted by researchers at the University of Indonesia has found that probiotic supplementation can significantly decrease the severity of atopic dermatitis (AD) in adults, thereby improving their overall quality of life. AD is a chronic skin disease characterized by abnormal skin barrier function and heightened immunologic sensitization. The study suggests that probiotics may offer potential therapeutic benefits in managing this condition and improving the quality of life for adult AD patients. The research was conducted using a systematic review and meta-analysis of randomized controlled trials. [Extracted from the article]

Researchers at Wake Forest University School of Medicine have conducted a study on the use of biologics and small molecule targeted therapies for pediatric dermatological conditions such as alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa. The study found that these therapies have significantly improved the management of these chronic skin conditions. The FDA has approved several biologics and small molecule therapies for pediatric patients, with others currently in clinical trials. These treatments have shown higher efficacy and improved safety profiles compared to traditional medications. The success of these clinical trials could lead to their inclusion in treatment guidelines, offering new avenues for effective disease management and improving pediatric health outcomes. [Extracted from the article]

A report from Peking University in Beijing, China, discusses the global, regional, and national burden of pediatric atopic dermatitis (AD). The researchers analyzed data from 1990 to 2019 and found that global cases of pediatric AD increased by approximately 5.7 million during this period. However, the age-standardized prevalence and incidence of AD slightly decreased. The study also identified regional disparities, with the highest increase in cases occurring in low socio-demographic index regions and the highest decrease in high socio-demographic index regions. The researchers concluded that region-specific strategies are necessary to reduce the burden of pediatric AD. [Extracted from the article]

A systematic review conducted by researchers at the National and Kapodistrian University of Athens evaluated the use of interleukin-4/interleukin-13 (IL-4/IL-13) inhibitors and Janus kinase (JAK) inhibitors in the restoration of skin barrier abnormalities in atopic dermatitis. The review included 12 studies, 10 of which focused on dupilumab (an IL-4/IL-13 inhibitor) and 2 on JAK inhibitors. The results showed that IL-4/IL-13 inhibitors were effective in improving skin barrier function, but more research is needed to establish the definitive role of IL-4/IL-13 inhibitors and JAK inhibitors in this context. The study highlights the burden of atopic dermatitis on patients' quality of life and the need for further investigation into potential treatments. [Extracted from the article]

A recent study conducted by researchers at the University of Amsterdam investigated the incidence and progression of (hyper)eosinophilia in patients with atopic dermatitis (AD) who were treated with dupilumab. The study found that 38.5% of patients had (hyper)eosinophilia at baseline or during treatment, with eosinophilia peaking at 6 months and normalizing by 18-24 months. Although one patient discontinued dupilumab due to persistent hypereosinophilia, overall, eosinophilia did not significantly affect treatment outcomes. The study concluded that dupilumab is a viable treatment option for patients with AD, regardless of baseline eosinophilia. [Extracted from the article]

A recent study conducted in Rome, Italy, explored the effects of dupilumab, a monoclonal antibody used to treat atopic dermatitis (AD), on patients with AD and food allergies. The study found that treatment with dupilumab resulted in a significant decrease in specific IgE levels and molecular components associated with food allergies. The researchers suggest that modulating type 2 immunity may reduce IgE-mediated responses and alleviate allergic symptoms in patients with multiple sensitivities. Further randomized controlled trials are needed to confirm the potential of dupilumab in treating IgE-mediated food allergies. [Extracted from the article]

A recent study conducted by the Medical University of Silesia in Katowice, Poland, has explored the relationship between IL-22 and atopic dermatitis (AD). Atopic dermatitis is a chronic inflammatory skin condition with diverse clinical manifestations. The study found that elevated levels of IL-22 in patients with AD are associated with increased proliferation of keratinocytes, alterations in the skin microbiota, and impaired epidermal barrier function, all of which contribute to the characteristic symptoms of AD. This research provides valuable insights into potential therapeutic targets and drug candidates for the management of AD. [Extracted from the article]

A study conducted by the Institute of Child Health in West Bengal, India, examined the efficacy and safety of oral tofacitinib in patients with refractory moderate to severe atopic dermatitis (AD). The study included 16 adult patients who had previously undergone systemic therapy with inadequate response. Over a 6-month trial period, the patients showed significant improvement in severity scores, quality of life, and no severe adverse reactions were noted. The research concluded that tofacitinib is a safe and effective treatment option for recalcitrant moderate to severe adult AD. [Extracted from the article]

Researchers at the University of Gothenburg have conducted a study on the effect of phototherapy on systemic inflammation in patients with inflammatory skin disease, specifically atopic dermatitis (AD) and psoriasis. The study found that narrowband-ultraviolet B (NB-UVB) phototherapy led to a decrease in vitamin D-binding protein (DBP) levels in psoriasis patients, suggesting a potential systemic anti-inflammatory effect. The researchers also observed improvements in disease severity and vitamin D levels after NB-UVB treatment. The study suggests that measuring vitamin D levels may help identify patients who would benefit the most from NB-UVB phototherapy. [Extracted from the article]

A study conducted by researchers at Dongguk University College of Medicine in South Korea has found that Agrimonia coreana extract (AC) may be effective in treating atopic dermatitis (AD). AD is a common allergic inflammatory skin condition characterized by severe itching, skin lichenification, and chronic inflammation. Traditional treatments, such as topical corticosteroids, have limitations due to long-term side effects, so safer alternatives are needed. The study showed that AC inhibits CRAC channel activity, reducing intracellular calcium signaling and T cell proliferation. In a mouse model of AD, AC significantly improved symptoms, histological parameters, and skin barrier function. Further research is needed to explore the potential of AC as a treatment for AD. [Extracted from the article]

A recent study conducted by researchers at the University of Occupational and Environmental Health in Fukuoka, Japan, explored the treatment of immunoglobulin G4-related disease (a condition that affects multiple organs) complicated by atopic dermatitis. The researchers found that glucocorticoids, commonly used to treat this disease, are often ineffective and can have toxic side effects. However, they observed that the introduction of upadacitinib, a medication that inhibits Janus kinase 1, resulted in remission of both atopic dermatitis and immunoglobulin G4-related disease without the need for increased glucocorticoid dosage. The study suggests that targeting specific signaling pathways may be a promising approach for treating these conditions. [Extracted from the article]

The article focuses on a clinical trial assessing the safety, tolerability, and pharmacokinetics of PF-07832837 in both healthy adults and patients with moderate to severe atopic dermatitis. Topics include evaluating drug safety; analyzing pharmacokinetics and pharmacodynamics; and monitoring effects on atopic dermatitis symptoms.

The article reviews the role of nemolizumab in treating moderate-to-severe atopic dermatitis in adults, highlighting its potential efficacy and safety. Topics discussed include ongoing clinical trials, common adverse effects such as nasopharyngitis, and the overall promise of nemolizumab as a treatment option.

The article reviews the Eczema Area and Severity Index (EASI) after 20 years of use, highlighting its validation and current challenges in measuring atopic dermatitis. Topics discussed include its performance across various severities, validation gaps especially in diverse populations, and the potential of technological adaptations for remote assessments.

A recent qualitative study conducted by researchers at the University of Paris-Est aimed to explore the experiences and expectations of adults with atopic dermatitis (AD) in order to improve their well-being. The study found that AD patients reported a significant burden due to the psychosocial impact of the condition, including emotional distress and daily life impediments. The researchers concluded that dermatological care should take into account patients' preferences and promote collaborative discussions between patients and physicians to improve treatment satisfaction. This information is available in the British Journal of Dermatology. [Extracted from the article]

A report from researchers at Najran University in Saudi Arabia discusses the knowledge of pharmacists in Saudi Arabia regarding the use of topical corticosteroids in the treatment of atopic dermatitis. The study found that a significant number of pharmacists provided incorrect answers about the use of topical corticosteroids, with 54.9% showing poor knowledge and only 45.1% having adequate knowledge. The research suggests that promoting continuous education and implementing formal undergraduate training programs could improve pharmacists' understanding of topical corticosteroid use in atopic dermatitis. [Extracted from the article]

Researchers from the University of Augsburg in Germany have published a report on atopic dermatitis (AD) in the journal Allergy. The report discusses the 4th Davos Declaration, which was developed during the Global Allergy Forum in Davos. The declaration aims to improve the care of patients with AD by uniting experts and stakeholders and addressing the challenges in research, treatment, and management of the condition. The report emphasizes the need for a holistic approach that combines research, education, and clinical application to improve patient outcomes. [Extracted from the article]

A patent application has been filed for a new therapeutic target for allergic inflammatory diseases such as atopic dermatitis and asthma. The invention involves the use of an inhibitor of matrix metalloproteinase 13 (MMP13) to treat these conditions. Experimental data has shown that deletion of the MMP13 gene can attenuate allergic inflammation and prevent tissue pathology in mouse models. The inhibitor of MMP13 can be administered topically or systemically, and may be used in combination with other therapeutic agents. This new therapy has the potential to provide broader effectiveness against allergic diseases. [Extracted from the article]

A new report from the University of Southampton in the United Kingdom discusses the development of a flexible, wearable interdigitated capacitive sensor for monitoring biomarkers of atopic dermatitis (AD). The sensor is designed to detect biomarkers of AD and estimate the severity of the condition. It has a compact and flexible footprint, making it compatible with a wearable and noninvasive system. The sensor shows promising prospects for remote patient care, enabling accurate diagnosis, treatment monitoring, and personalized interventions for AD. [Extracted from the article]

Researchers at Tung's Taichung Metro-harbor Hospital in Taiwan have published a case report on eczema herpeticum, a skin complication associated with the herpes simplex virus. The condition is characterized by painful, scaling skin and the presence of vesicular lesions, often accompanied by secondary infection. The researchers presented a case of eczema herpeticum in a young patient with ankylosing spondylitis who did not have a compromised immune system. The patient's symptoms improved with antiviral and antibiotic treatments. The incidence of eczema herpeticum has been increasing due to factors such as the higher prevalence of HIV/AIDS, increased use of immunosuppressive therapy, and a growing incidence of atopic dermatitis. [Extracted from the article]

A study conducted by researchers at the Lake Erie College of Osteopathic Medicine in Bradenton, Florida, examined the effectiveness of at-home handheld narrow-band ultraviolet B (NB-UVB) phototherapy as an adjunctive treatment for atopic dermatitis (AD). The study involved 52 patients with mild to severe AD who self-administered phototherapy three times a week for 12 weeks. The results showed that 67% of patients experienced disease improvement, and overall satisfaction and adherence rates were high. The researchers concluded that at-home handheld NB-UVB phototherapy is an effective and well-tolerated treatment option for patients with refractory AD. [Extracted from the article]

A study conducted by researchers at Jichi Medical University in Tochigi, Japan, explores the role of acid ceramidase in the development of atopic dermatitis (AD). The researchers found that overexpression of the b-subunit of acid ceramidase in the epidermis of mice led to AD-like skin symptoms. The mice exhibited decreased levels of ceramides in the stratum corneum, disrupted barrier functions, increased expression of IL-33 in the epidermis, and an accumulation of macrophages in the dermis. These findings suggest that acid ceramidase plays a significant role in the development of atopic dry skin symptoms. [Extracted from the article]

A study conducted by the University of Cape Town in South Africa investigated the genomic diversity of Staphylococcus aureus (S. aureus) associated with pediatric atopic dermatitis (AD). The study found that S. aureus isolates from children with AD showed greater resistance to certain antibiotics and formed stronger biofilms compared to isolates from children without AD. However, there was no significant difference in the distribution of immune evasion cluster types between the two groups. The researchers concluded that further studies are needed to understand the pathological implications of S. aureus colonization in AD. [Extracted from the article]

A recent study conducted by Northwestern University examined the relationship between attention deficit hyperactivity disorder (ADHD) and moderate-to-severe atopic dermatitis (AD) in adolescents. The study found that adolescents with AD did not demonstrate greater attention problems compared to their peers without AD. The research utilized objective, computer-based tests to evaluate attention and also assessed other factors such as sleep, quality of life, and comorbid anxiety and depressive symptoms. The findings suggest that attention problems may not be a significant concern for adolescents with moderate-to-severe AD. [Extracted from the article]

A recent study conducted by the University of Zurich in Switzerland has found that dupilumab, a monoclonal antibody therapy, can effectively reduce the frequency of IgGCD23IL-4Ra type 2 memory B cells (MBC2s) and total IgE levels in pediatric patients with atopic dermatitis (AD). The study compared the effects of dupilumab treatment with alternative therapies on a group of pediatric patients with AD. The results showed a significant reduction in MBC2 frequency and total IgE levels among patients treated with dupilumab, indicating a novel mechanism through which the therapy influences the atopic signature. This research has been peer-reviewed and provides valuable insights into the treatment of AD in pediatric patients. [Extracted from the article]

Childhood obesity has been found to contribute to the development of immune-mediated skin diseases (IMSDs) such as alopecia areata, atopic dermatitis, and psoriasis, according to a study published in the Journal of Investigative Dermatology. The study analyzed data from over 2 million Korean children from 2009 to 2020 and found that maintaining a healthy weight could potentially lower the risk of developing these skin conditions. The researchers emphasized the importance of promoting weight maintenance and implementing interventions, including nutritional strategies, to decrease body weight and reduce the risk of developing IMSDs in children. [Extracted from the article]

A report from Sungkyunkwan University School of Medicine in Seoul, South Korea discusses the development of atopic dermatitis (AD) and food allergies (FA) in infants. The research highlights the multifactorial nature of AD and FA, involving genetic susceptibility, skin-barrier dysfunction, microbiome alterations, and immune dysregulation. The study suggests that reliable biomarkers are needed to identify high-risk individuals for more effective preventive strategies. The researchers propose using a non-invasive technique called skin tape stripping (STS) to analyze the stratum corneum and gain insights into the early pathogenesis and potential progression of AD and FA. [Extracted from the article]